DENVER, March 22, 2021 /PRNewswire/ — Akerna (Nasdaq: KERN), an enterprise software, leading compliance technology provider and developer of the cannabis industry’s first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform®), today reported its unaudited financial results for the quarter ended December 31, 2020.
“In the December quarter we delivered strong financial results, with 38 percent software growth year over year and 36 percent sequential improvement in adjusted EBITDA,” said Jessica Billingsley, CEO of Akerna. “With the recent announced plans to acquire Viridian, we continue to bolster the strength of our channel connections with existing ERP providers. As we prepare for a post-legalization landscape and the industry continues to consolidate and mature, we firmly believe enterprise capabilities, including comprehensive compliance solutions and financial reporting integrations, will become increasingly important to the future leaders of the cannabis industry.”
Quarter Ended December 31, 2020 Financial Highlights
See “Explanation of Non-GAAP Financial Measures” below
Quarter Ended December 31, 2020 Key Metrics
Quarter Ended December 31, 2020 Operational Highlights
Conference Call Details
Akerna will host a conference call tomorrow, Tuesday, March 23, 2021, at 8:30 a.m. Eastern Time to discuss its financial results and business highlights. A question-and-answer session will follow prepared remarks.
Interested parties may listen to the call by dialing:
Toll-Free: 1-877-407-3982
Toll / International: 1-201-493-6780
Conference ID: 13717601
The conference call will also be available via a live, listen-only webcast and can be accessed through the Investor Relations section of Akerna’s website, https://ir.akerna.com/
To be included on the Company’s email distribution list, please sign up at https://ir.akerna.com/news-events/email-alerts
About Akerna
Akerna (Nasdaq: KERN) is an enterprise software company focused on compliantly serving the cannabis, hemp, and CBD industry. First launched in 2010, Akerna has tracked more than $20 billion in cannabis sales to date and is the first cannabis software company listed on Nasdaq. The company’s cornerstone technology, MJ Platform, the world’s leading infrastructure as a service platform, powers retailers, manufacturers, brands, distributors, and cultivators.
For more information, visit https://www.akerna.com/.
Forward Looking Statements
Certain statements made in this release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. Such forward-looking statements include but are not limited to statements regarding our preparation for a potential post-legalization landscape, our believe enterprise capabilities, including comprehensive compliance solutions and financial reporting integrations, will become increasingly important to the future leaders of the cannabis industry and the timing for management’s conference call in relation to our quarterly results. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of significant known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside Akerna’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others that may affect actual results or outcomes, include (i) Akerna’s ability to maintain relationships with customers and suppliers and retain its management and key employees, (ii) changes in applicable laws or regulations, (iii) changes in the market place due to the coronavirus pandemic or other market factors, (iv) and other risks and uncertainties disclosed from time to time in Akerna’s filings with the U.S. Securities and Exchange Commission, including those under “Risk Factors” therein. You are cautioned not to place undue reliance on forward-looking statements. All information herein speaks only as of the date hereof, in the case of information about Akerna, or the date of such information, in the case of information from persons other than Akerna. Akerna undertakes no duty to update or revise the information contained herein. Forecasts and estimates regarding Akerna’s industry and end markets are based on sources believed to be reliable; however, there can be no assurance these forecasts and estimates will prove accurate in whole or in part.
Explanation of Non-GAAP Financial Measures:
In addition to our results determined in accordance with U.S. generally accepted accounting principles (“GAAP”), we believe the following non-GAAP measures are useful in evaluating our operating performance. We use the following non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP.
Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. We attempt compensate for these limitations by providing specific information regarding the GAAP items excluded from these non-GAAP financial measures.
Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.
Adjusted EBITDA
We believe that Adjusted EBITDA, when considered with the financial statements determined in accordance with GAAP, is helpful to investors in understanding our performance and allows for comparison of our performance and credit strength to our peers. Adjusted EBITDA should not be considered alternatives to net loss as determined in accordance with GAAP as indicators of our performance or liquidity.
We define EBITDA as net loss before interest expense, provision for income taxes, depreciation and amortization. We calculate Adjusted EBITDA as EBITDA further adjusted to exclude the effects of the following items for the reasons set forth below:
Related Non-GAAP Expense Measure
We reference in our earnings call non-GAAP Operating Expenses. We believe that this non-GAAP financial measure, when considered with the financial statements determined in accordance with GAAP, is helpful to management and investors in understanding our performance quarter over quarter and to the comparable quarter in our prior fiscal year by excluding the same items we exclude from EBITDA to derive Adjusted EBITDA that are included in GAAP operating expenses, as set forth above (impairment of long-lived assets, stock-based compensation expense, costs incurred with business combinations, costs incurred in connection with debt issuance, restructuring costs and certain other non-operating expenses, as described above) for the same reasons stated above– principally, that these expenses are not, in management’s opinion, easily comparable across reporting periods, are not reflective of ongoing operations and/or are not representative of our operating performance.
We define non-GAAP Operating Expenses, as GAAP Operating Expenses, excluding impairment of long-lived assets, stock-based compensation expense, costs incurred with business combinations, costs incurred in connection with debt issuance and restructuring costs.
This non-GAAP expense measure should not be considered an alternative to the corresponding GAAP financial measure as determined in accordance with GAAP as an indicator of our performance or liquidity. Please review the tables provided below, for a reconciliation of this non-GAAP expense measure to the corresponding GAAP financial measure.
Akerna Corp. |
|||||
Consolidated Balance Sheet |
|||||
As of December 31, 2020, June 30, 2020 and 2019 |
|||||
December 31 |
June 30 |
June 30 |
|||
2020 |
2020 |
2019 |
|||
(unaudited) |
|||||
Assets |
|||||
Current assets |
|||||
Cash |
$ 17,840,640 |
$ 24,155,828 |
$ 21,867,289 |
||
Restricted cash |
500,000 |
500,000 |
500,000 |
||
Accounts receivable, net |
1,753,547 |
1,861,534 |
1,257,274 |
||
Prepaid expenses & other current assets |
2,458,727 |
1,215,341 |
577,674 |
||
Total current assets |
22,552,914 |
27,732,703 |
24,202,237 |
||
Fixed assets, net |
1,193,433 |
131,095 |
– |
||
Investment, net |
233,665 |
246,308 |
– |
||
Capitalized software, net |
3,925,738 |
2,629,304 |
– |
||
Intangible assets, net |
7,388,795 |
7,493,975 |
– |
||
Goodwill |
41,874,527 |
20,254,309 |
– |
||
Other noncurrent assets |
– |
41,925 |
– |
||
Total assets |
$ 77,169,072 |
$ 58,529,619 |
$ 24,202,237 |
||
Liabilities and stockholders’ equity |
|||||
Current liabilities |
|||||
Accounts Payable, accrued expenses and other current liabilities |
$ 3,188,575 |
$ 4,861,928 |
$ 1,818,116 |
||
Contingent consideration payable |
– |
389,000 |
– |
||
Deferred revenue |
843,900 |
368,685 |
624,387 |
||
Current portion of long-term debt |
11,707,363 |
6,135,364 |
– |
||
Total current liabilities |
15,739,838 |
11,754,977 |
2,442,503 |
||
Long-term debt, noncurrent |
3,895,237 |
10,200,236 |
– |
||
Total liabilities |
$ 19,635,075 |
$ 21,955,213 |
$ 2,442,503 |
||
Stockholders’ equity |
|||||
Preferred stock |
– |
– |
– |
||
Exchangeable preferred stock |
20,405,219 |
– |
– |
||
Common stock |
1,990 |
1,321 |
1,059 |
||
Additional paid-in capital |
95,090,883 |
72,906,924 |
47,325,421 |
||
Accumulated other comprehensive (loss) income |
(91,496) |
63,000 |
– |
||
Accumulated deficit |
(57,872,599) |
(41,101,091) |
(25,566,746) |
||
Total stockholders’ equity |
$ 57,533,997 |
$ 31,870,154 |
$ 21,759,734 |
||
Noncontrolling interests in consolidated subsidiary |
– |
4,704,252 |
– |
||
Total stockholders’ equity |
57,533,997 |
36,574,406 |
21,759,734 |
||
Liabilities and stockholders’ equity |
$ 77,169,072 |
$ 58,529,619 |
$ 24,202,237 |
||
Akerna Corp. |
||||||||||||||||
Consolidated Statement of Operations |
||||||||||||||||
For the three months and six months ended December 31, 2020 and 2019, and years ended June 30, 2020 and 2019 |
||||||||||||||||
Three Months Ended December 31 |
Six Months Ended December 31 |
Year Ended June 30 |
||||||||||||||
2020 |
2019 |
2020 |
2019 |
2020 |
2019 |
|||||||||||
(unaudited) |
(unaudited) |
(unaudited) |
(unaudited) |
|||||||||||||
Revenue |
||||||||||||||||
Software |
$ 3,443,392 |
$ 2,498,174 |
$ 6,766,985 |
$ 4,802,654 |
$ 9,976,580 |
$ 8,256,492 |
||||||||||
Consulting |
583,512 |
725,000 |
916,099 |
1,556,363 |
2,379,947 |
2,307,129 |
||||||||||
Other revenue |
83,876 |
83,029 |
141,700 |
140,076 |
216,749 |
259,496 |
||||||||||
Total Revenue |
4,110,780 |
3,306,203 |
7,824,784 |
6,499,093 |
12,573,276 |
10,823,117 |
||||||||||
Cost of revenue |
1,401,103 |
1,615,239 |
3,141,041 |
2,994,940 |
6,209,724 |
4,633,844 |
||||||||||
Gross profit |
2,709,677 |
1,690,964 |
4,683,743 |
3,504,153 |
6,363,552 |
6,189,273 |
||||||||||
Total Operating expenses |
||||||||||||||||
Product development |
1,407,262 |
623,501 |
3,166,088 |
1,234,403 |
3,206,310 |
5,565,097 |
||||||||||
Sales and marketing |
1,830,526 |
2,132,004 |
3,928,028 |
3,725,012 |
7,792,480 |
7,498,114 |
||||||||||
General and administrative |
1,964,880 |
2,664,400 |
4,435,067 |
4,655,207 |
11,320,715 |
5,638,408 |
||||||||||
Depreciation and amortization |
836,215 |
86,768 |
2,007,237 |
104,667 |
1,315,898 |
– |
||||||||||
Impairment of long-lived assets |
6,887,000 |
– |
6,887,000 |
– |
– |
– |
||||||||||
Total operating expenses |
12,925,883 |
5,506,673 |
20,423,420 |
9,719,289 |
23,635,403 |
18,701,619 |
||||||||||
Loss from operations |
(10,216,206) |
(3,815,709) |
(15,739,677) |
(6,215,136) |
(17,271,851) |
(12,512,346) |
||||||||||
Other income (expense) |
||||||||||||||||
Interest income (expense) |
(189,397) |
51,857 |
(193,084) |
125,239 |
156,678 |
91,239 |
||||||||||
Change in fair value of |
(1,739,273) |
– |
(961,273) |
– |
766,000 |
– |
||||||||||
Other expense |
(59,272) |
157 |
(59,272) |
(130) |
(254) |
17,892 |
||||||||||
Total other income (expense) |
(1,987,942) |
52,014 |
(1,213,629) |
125,109 |
922,424 |
109,131 |
||||||||||
Net loss before income tax |
(12,204,148) |
(3,763,695) |
(16,953,306) |
(6,090,027) |
(16,349,427) |
(12,403,215) |
||||||||||
Income tax expense |
(200) |
– |
(200) |
– |
(30,985) |
– |
||||||||||
Equity in losses of investee |
(11,109) |
– |
(12,643) |
– |
(3,692) |
– |
||||||||||
Net Loss |
(12,215,457) |
(3,763,695) |
(16,966,149) |
(6,090,027) |
(16,384,104) |
(12,403,215) |
||||||||||
Net loss attributable to |
– |
– |
8,815 |
– |
849,759 |
– |
||||||||||
Net loss attributable to Akerna |
$(12,215,457) |
$ (3,763,695) |
$(16,957,333) |
$ (6,090,027) |
$(15,534,345) |
$(12,403,215) |
||||||||||
Basic and diluted weighted average |
18,138,921 |
10,958,772 |
16,056,030 |
10,918,942 |
11,860,212 |
6,045,382 |
||||||||||
$ (0.67) |
$ (0.34) |
$ (1.06) |
$ (0.56) |
$ (1.31) |
$ (2.05) |
|||||||||||
Akerna Corp. |
|||||
Consolidated Statement of Cash Flows |
|||||
For the six months ended December 31, 2020, and year ended June 30, 2020 and 2019 |
|||||
Six Months
December 31
|
Year Ended June 30 |
||||
2020 |
2020 |
2019 |
|||
(unaudited) |
|||||
Cash flows from operating activities |
|||||
Net Loss |
$ (16,966,149) |
$ (16,384,104) |
$ (12,403,215) |
||
Adjustment to reconcile net loss to net cash used in operating activities |
|||||
Bad debt expense |
72,832 |
1,094,507 |
345,941 |
||
Stock-based compensation expense |
1,197,589 |
1,166,130 |
3,884,111 |
||
Depreciation and amortization |
2,007,237 |
1,315,898 |
– |
||
Impairment of long-lived asset |
6,887,000 |
– |
– |
||
Non-cash interest expense |
32,732 |
– |
– |
||
Equity in losses of investee |
12,643 |
3,692 |
– |
||
Gain on sale of fixed asset |
84,835 |
– |
– |
||
Debt issuance costs classified as financing |
– |
1,177,390 |
– |
||
Change in fair value of convertible notes |
961,272 |
(766,000) |
– |
||
Change in fair value of contingent consideration |
(993,000) |
(998,000) |
– |
||
Changes in operating assets and liabilities: |
|||||
Accounts receivable |
1,008,775 |
(1,621,262) |
(1,572,889) |
||
Prepaid expenses and other current assets |
(460,964) |
(592,807) |
(351,144) |
||
Other assets |
81,924 |
(58,925) |
– |
||
Accounts payable and accrued liabilities |
(2,749,766) |
1,602,751 |
893,845 |
||
Deferred revenue |
(94,088) |
(286,922) |
154,756 |
||
Net cash used in operating activities |
(8,917,128) |
(14,347,652) |
(9,048,595) |
||
Cash flows from investing activities |
|||||
Developed software additions |
(1,847,710) |
(3,102,728) |
– |
||
Furniture, fixtures and equipment additions |
(12,203) |
(156,636) |
– |
||
Cash paid for business combinations, net of cash acquired |
(5,067,740) |
(88,720) |
– |
||
Investment in equity method investee |
– |
(250,000) |
– |
||
Cash received in connection with reverse merger |
– |
– |
18,843,483 |
||
Net Cash provided by investing activities |
(6,927,653) |
(3,598,084) |
18,843,483 |
||
Cash flows from financing activities |
|||||
Proceeds from the issuance of long-term debt |
– |
17,164,600 |
– |
||
Payments on debt |
(1,500,000) |
– |
– |
||
Cash paid for debt issuance costs |
– |
(1,177,390) |
– |
||
Proceeds from the exercise of warrants |
– |
4,247,065 |
– |
||
Proceeds from the issuance of common stock |
11,032,380 |
– |
10,000,000 |
||
Net cash provided by financing activities |
9,532,380 |
20,234,275 |
10,000,000 |
||
Effect of exchange rate changes on cash and restricted cash |
(2,787) |
– |
– |
||
Net (decrease) increase in cash and restricted cash |
$ (6,315,188) |
$ 2,288,539 |
$ 19,794,888 |
||
Cash and restricted cash, beginning of period |
24,655,828 |
22,367,289 |
2,572,401 |
||
Cash and restricted cash, end of period |
$ 18,340,640 |
$ 24,655,828 |
$ 22,367,289 |
||
Cash paid for taxes |
$ – |
$ – |
$ – |
||
Cash paid for interest |
$ 150,000 |
$ – |
$ – |
||
Akerna Corp. |
|||||||||||
Earnings Before Interest, Taxes, Depreciation and Amortization, and Adjusted EBITDA |
|||||||||||
For the three months and six months ended December 31, 2020 and 2019, and years ended June 30, 2020 and 2019 |
|||||||||||
The reconciliation of net income to EBITDA and Adjusted EBITDA is as follows: |
|||||||||||
(unaudited) |
|||||||||||
Three Months Ended December 31 |
Six Months Ended December 31 |
Year Ended June 30 |
|||||||||
2020 |
2019 |
2020 |
2019 |
2020 |
2019 |
||||||
Net Loss |
$(12,215,457) |
$ (3,763,695) |
$(16,966,149) |
$ (6,090,027) |
$(16,384,104) |
$(12,403,215) |
|||||
Interest (income) expense and |
1,928,670 |
(51,857) |
1,154,356 |
(125,239) |
(922,678) |
(91,239) |
|||||
Depreciation and amortization |
836,215 |
86,768 |
2,007,237 |
104,667 |
1,315,898 |
– |
|||||
Income tax provision |
200 |
– |
200 |
– |
30,985 |
– |
|||||
EBITDA |
$ (9,450,372) |
$ (3,728,784) |
$(13,804,355) |
$ (6,110,599) |
$(15,959,899) |
$(12,494,454) |
|||||
Impairment of long-lived assets |
6,887,000 |
– |
6,887,000 |
– |
– |
– |
|||||
Stock-based compensation |
516,170 |
331,485 |
1,197,589 |
492,650 |
1,166,130 |
3,884,110 |
|||||
Business combination and merger |
142,639 |
733,867 |
1,094,503 |
733,867 |
2,979,228 |
1,080,870 |
|||||
Debt issuance costs related to fair |
96,427 |
– |
139,594 |
– |
1,177,390 |
– |
|||||
Restructuring charges |
421,957 |
– |
490,146 |
– |
– |
– |
|||||
Changes in fair value of |
(604,000) |
– |
(993,000) |
– |
(998,000) |
– |
|||||
Equity in losses of investee |
11,109 |
– |
12,643 |
– |
3,692 |
– |
|||||
Other non-operating expenses |
59,272 |
(157) |
59,272 |
130 |
– |
– |
|||||
Adjusted EBITDA |
$ (1,919,798) |
$ (2,663,589) |
$ (4,916,607) |
$ (4,883,952) |
$(11,631,459) |
$ (7,529,474) |
|||||
Akerna Corp. |
|||||||||||
The reconciliation of operating expenses to non-GAAP operating expenses is as follows: |
|||||||||||
(unaudited) |
|||||||||||
Three Months Ended December 31 |
Six Months Ended December 31 |
Year Ended June 30 |
|||||||||
2020 |
2019 |
2020 |
2019 |
2020 |
2019 |
||||||
Operating expenses |
$ 12,925,883 |
$ 5,506,673 |
$ 20,423,420 |
$ 9,719,289 |
$ 23,635,403 |
$ 18,701,619 |
|||||
Adjustments: |
|||||||||||
Depreciation and amortization |
836,215 |
86,768 |
2,007,237 |
104,667 |
1,315,898 |
– |
|||||
Impairment of long-lived assets |
6,887,000 |
– |
6,887,000 |
– |
– |
– |
|||||
Stock-based compensation |
474,196 |
331,485 |
1,137,905 |
492,650 |
1,166,130 |
3,884,110 |
|||||
Business combination and |
142,639 |
733,867 |
1,094,503 |
733,867 |
2,979,228 |
1,080,870 |
|||||
Debt issuance costs related to |
96,427 |
– |
139,594 |
– |
1,177,390 |
– |
|||||
Restructuring charges |
421,957 |
– |
490,146 |
– |
– |
– |
|||||
Changes in fair value of |
(604,000) |
– |
(993,000) |
– |
(998,000) |
– |
|||||
Non-GAAP operating expenses |
$ 4,671,449 |
$ 4,354,553 |
$ 9,660,035 |
$ 8,388,105 |
$ 17,994,757 |
$ 13,736,639 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/akerna-announces-financial-results-for-the-quarter-ended-december-31-2020-301253196.html
SOURCE Akerna
The round is led by Danish VC Dreamcraft, together with biotech investor Lundbeckfonden BioCapital and…
BCC Research Identifies Key Sectors with Substantial Growth Potential, Forecasting Significant Market Expansion Through 2029.…
PALO ALTO, CA / ACCESSWIRE / July 3, 2024 / Bioz, Inc., a pioneering AI…
STOCKHOLM, SWEDEN / ACCESSWIRE / July 3, 2024 / iZafe Group (STO:IZAFE-B.ST) iZafe Group AB…
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza…
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation…